Zura Bio's stock is trading lower, likely due to profit-taking after a significant rally. The company has recently raised funds for trials and merged with JATT Acquisition Corp, which has attracted positive analyst coverage. This combination of factors suggests a short-term negative impact on the stock price as investors take profits, but the overall outlook remains positive.